Predictive value of early molecular response for deep molecular response in chronic phase of chronic myeloid leukemia
نویسندگان
چکیده
منابع مشابه
Monitoring molecular response in chronic myeloid leukemia.
Before the advent of tyrosine kinase inhibitor (TKI) therapy, the evaluation of hematologic and cytogenetic responses was sufficient to gauge treatment efficacy in patients with chronic myeloid leukemia. However, with more potent TKI therapies, the majority of patients achieve complete cytogenetic response. Furthermore, deeper molecular responses are now commonly achieved, necessitating a relia...
متن کاملPredictive value of early molecular response in patients with chronic myeloid leukemia treated with first-line dasatinib.
Dasatinib is effective therapy for newly diagnosed patients with chronic myeloid leukemia, but not all patients respond well. We analyzed the outcome of patients treated with dasatinib as first-line therapy to identify patients who are more likely to fare poorly. The 8.6% of patients who at 3 months had a BCR-ABL1/ABL1 ratio > 10% had a significantly worse 2-year cumulative incidence of complet...
متن کاملMolecular monitoring of response in patients with chronic myeloid leukemia.
PURPOSE To discuss the importance of regular, consistent use of molecular testing to monitor treatment response and minimal residual disease in patients with chronic myeloid leukemia (CML), as recommended in established practice guidelines. DESIGN This review outlines the efficacy of BCR-ABL1 tyrosine kinase inhibitors (TKIs) in eliciting significant treatment responses in patients with CML; ...
متن کاملMolecular response to imatinib in late chronic-phase chronic myeloid leukemia.
Imatinib is a tyrosine-kinase inhibitor that binds to ABL proteins and induces cytogenetic remissions in patients with chronic myeloid leukemia (CML). In these patients measuring response by molecular techniques is clearly required. We determined the cytogenetic and molecular response (CgR, MR) to imatinib in 191 patients with late chronic-phase Philadelphia-positive (Ph+) CML, previously treat...
متن کاملDeep molecular response in chronic myeloid leukemia: the new goal of therapy?
Chronic myeloid leukemia (CML) is caused by formation of the BCR-ABL1 fusion protein. Tyrosine kinase inhibitors (TKI) that target BCR-ABL1 are now the standard of care for patients with CML. Molecular monitoring of residual BCR-ABL1 mRNA transcripts, typically performed using real-time quantitative PCR, has improved treatment management, particularly for patients with CML in chronic phase. Maj...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Medicine
سال: 2019
ISSN: 0025-7974,1536-5964
DOI: 10.1097/md.0000000000015222